Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMD +2.64%72 Debt-to-EBITDA is 4.31 as of Mar. 2026, which is 7% below its 10-year median of 4.61. GuruFocus rates BTMD with a GF Score™ of 72/100 and a GF Value™ of $3.07 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Biote ranks worse than 58.37% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Biote's Debt-to-EBITDA or its related term are showing as below:
BTMD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.04 Med: 4.61 Max: 15.13
Current: 2.91
During the past 7 years, the highest Debt-to-EBITDA Ratio of Biote was 15.13. The lowest was 1.04. And the median was 4.61.
BTMD's Debt-to-EBITDA is ranked worse than 58.37% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs BTMD: 2.91
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Biote Debt-to-EBITDA Related Terms
Biote Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Biote's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTMD vs DCGO, PARK, PIII: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Biote's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biote's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Biote (BTMD) has a Debt-to-EBITDA of 4.31 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biote. This is near median its historical median of 4.61. Over the past decade, Biote's Debt-to-EBITDA has ranged from 1.04 to 15.13. According to the industry distribution chart, Biote ranks #279 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 58.4%.
Is Biote's Debt-to-EBITDA too high?
Biote's current Debt-to-EBITDA of 4.31 is near median its 10-year median of 4.61. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 15.13. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. Biote's value of 4.31 is 91.6% above this industry median. Based on the distribution chart, Biote ranks #279 out of 478 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Biote has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Debt-to-EBITDA compare to DCGO and PARK?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #279 out of 478 companies for Debt-to-EBITDA. This places Biote in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. Biote's value of 4.31 is 91.6% above this benchmark. Historically, Biote's own Debt-to-EBITDA has ranged from 1.04 to 15.13 over the past decade. While the company's 10-year median is 4.61 vs. the industry median of 2.25, Biote has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biote's current Debt-to-EBITDA of 4.31 is 91.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biote. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current Debt-to-EBITDA is 4.31, which is near median its own 10-year median of 4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $2.31 — trading 24.7% below its estimated fair value. The current Debt-to-EBITDA is 4.31, which is near median its 10-year median of 4.61 and 91.6% above the Healthcare Providers & Services industry median of 2.25. Biote's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Biote (BTMD), the current Debt-to-EBITDA is 4.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biote (BTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Biote stock appears to be undervalued.
The current stock price of $2.31 is trading 24.7% below its estimated GF Value™ of $3.07.
GuruFocus considers Biote to be Modestly Undervalued.
Key valuation signals for BTMD:
Debt-to-EBITDA: 4.31 (near median its 10-year median of 4.61)
GF Value™: $3.07 vs. price of $2.31 (24.7% below fair value)
Industry Position: 91.6% above the Healthcare Providers & Services median (#279 of 478)
No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
72GF Score
Get the complete analysis for BTMD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMD has been successfully added to your 
